Cargando…

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment

Cenicriviroc, a dual CCR2/CCR5 antagonist, is being evaluated for treatment of nonalcoholic steatohepatitis and liver fibrosis (CENTAUR; NCT02217475). As it is metabolized by the liver, cenicriviroc was investigated in hepatic‐impaired participants for pharmacokinetic changes. Participants with mild...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lefebvre, E, Gottwald, M, Lasseter, K, Chang, W, Willett, M, Smith, PF, Somasunderam, A, Utay, NS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351328/ https://www.ncbi.nlm.nih.gov/pubmed/27169903 http://dx.doi.org/10.1111/cts.12397

Ejemplares similares

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015)

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022)

Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy
por: Kwiatkowski, Klaudia, et al.
Publicado: (2020)

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmd(mdx-4Cv)) mice
por: Liang, Feng, et al.
Publicado: (2018)

Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant
por: Skendelas, J.P., et al.
Publicado: (2021)

Promising Modulatory Effects of Cenicriviroc on the Progression of Mouse Colorectal Cancer through Inhibition of CCR2_CCL2 Signaling Pathway
por: Eslami, Mina, et al.
Publicado: (2023)

Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model
por: Okamoto, Masayuki, et al.
Publicado: (2013)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
por: Bekker, Pirow, et al.
Publicado: (2015)

Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas’ Heart Disease: Antagonistic Participation of CCR1(+) and CCR5(+) Cells in Chronic Chagasic Cardiomyopathy
por: Batista, Angelica Martins, et al.
Publicado: (2018)

CCR3 antagonist impairs estradiol-induced eosinophil migration to the uterus in ovariectomized mice
por: Araújo, J.M.D., et al.
Publicado: (2019)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands
por: Korbecki, Jan, et al.
Publicado: (2020)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
por: Puengel, Tobias, et al.
Publicado: (2022)

Systematic Assessment of Chemokine Signaling at Chemokine Receptors CCR4, CCR7 and CCR10
por: Lim, Herman D., et al.
Publicado: (2021)

CCR5 and CXCR4 antagonist and agonist binding sites
por: Teintze, Martin, et al.
Publicado: (2006)

Evolution of coreceptor utilization to escape CCR5 antagonist therapy
por: Zhang, Jie, et al.
Publicado: (2016)

Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study
por: Kothandan, Gugan, et al.
Publicado: (2012)

Role of the Chemokine Receptors CCR1, CCR2 and CCR4 in the Pathogenesis of Experimental Dengue Infection in Mice
por: Guabiraba, Rodrigo, et al.
Publicado: (2010)

Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for T(H)2-Specific Chemokine Receptors CCR3, CCR4, and CCR8
por: Matsuo, Kazuhiko, et al.
Publicado: (2016)

In this Issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

IN THIS ISSUE OF CCR
por: Bellomo, Rinaldo
Publicado: (2023)

IN THIS ISSUE OF CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In this Issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In This Issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In this issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In this issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In this Issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

In this issue of CCR
por: Bellomo, Rinaldo
Publicado: (2023)

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
por: Okamoto, Mika, et al.
Publicado: (2020)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

In silco analysis of carboxamide derivatives of piperidine as potential antagonists of CCR5
por: Harishchander, A, et al.
Publicado: (2014)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis
por: Sun, Zhe, et al.
Publicado: (2011)

131 Expression of Chemokine Receptors CCR1, CCR3, CCR4, CCR5, CCR8 and CXCR3 in Human Nasal Polyps (NP); Comparison With NP From Allergic Patients With Aspirin Intolerance
por: Fundova, Petra, et al.
Publicado: (2012)

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4
por: Korbecki, Jan, et al.
Publicado: (2020)

Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes
por: Connolly, Kelli A., et al.
Publicado: (2016)

Cocycles of CCR flows
por: Bhat, BV Rajarama
Publicado: (2001)

Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
por: Brumme, CJ, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qourd3qq6dums4ni8kf1ufk1nv